DOCSLIB.ORG

From Novel Disease Genes to New Mouse Models - a Complementary Approach

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
From Novel Disease Genes to New Mouse Models - a Complementary Approach TECHNISCHE UNIVERSITÄT MÜNCHEN FAKULTÄT WISSENSCHAFTSZENTRUM WEIHENSTEPHAN FÜR ERNÄHRUNG, LANDNUTZUNG UND UMWELT LEHRSTUHL FÜR ENTWICKLUNGSGENETIK From Novel Disease Genes to New Mouse Models - A Complementary Approach Caroline Alexandra Biagosch Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Prof. Dr. Martin Hrab ĕ de Angelis Prüfer der Dissertation: 1. Priv.-Doz. Dr. Thomas Floss 2. Prof. Angelika Schniecke, Ph.D. Die Dissertation wurde am 10.10.2016 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 08.03.2017 angenommen. To my family. TABLE OF CONTENTS ABSTRACT ......................................................................................................................... 9 English .............................................................................................................................................. 9 German ........................................................................................................................................... 11 I. IDENTIFICATION OF A NEW DISEASE-ASSOCIATED GENE – FBXL4 .... 13 I.1. INTRODUCTION .............................................................................................................. 13 I.1.1. Genetic disease and mitochondriopathies .............................................................................13 I.1.2. Development of genetic disorders ..........................................................................................13 I.1.3. Mitochondria and oxidative phosphorylation .......................................................................14 I.1.4. Mitochondriopathies ...............................................................................................................15 I.1.5. Gene discovery approaches ....................................................................................................15 I.1.6. Functional validation of candidate genes ..............................................................................16 I.2. RESULTS ............................................................................................................................ 18 I.2.1. Identification of FBXL4 as a candidate gene for early-onset mitochondrial encephalopathy ........................................................................................................................................18 I.2.2. Molecular genetic analysis of FBXL4 ....................................................................................19 I.2.3. Clinical and biochemical features ..........................................................................................20 I.2.4. Validation of FBXL4 via cellular rescue experiments .........................................................21 I.2.5. Mutations in FBXL4 are related to a reduction of mitochondrial proteins .......................23 I.3. DISCUSSION ..................................................................................................................... 24 I.3.1. FBXL4 dysfunction causes a clinically and biochemically distinct phenotype ..................24 I.3.2. FBXL4 dysfunction causes a mitochondrial disorder ..........................................................25 I.3.3. Outlook: Relevance for diagnosis and protein function .......................................................27 II. GENERATION OF A MOUSE MODEL ( WDR45 KO) RESEMBLING THE HUMAN DISEASE BPAN ............................................................................................... 29 II.1. INTRODUCTION .............................................................................................................. 29 II.1.1. Generation of a knockout mouse model ................................................................................29 II.1.1.1. The use of mouse models and genetic engineering ......................................................................... 29 II.1.1.2. TALEN............................................................................................................................................... 30 II.1.1.3. CRISPR/Cas9 .................................................................................................................................... 31 5 TABLE OF CONTENTS II.1.1.4. The German Mouse Clinic and the establishment of a mouse model ........................................... 33 II.1.2. The human disease BPAN and the corresponding Wdr45 knockout ................................. 34 II.1.2.1. Neurodegeneration with brain iron accumulation (NBIA) ........................................................... 34 II.1.2.2. Beta-propeller protein-associated neurodegeneration (BPAN) .................................................... 35 II.1.2.3. Genetics of BPAN and the disease-associated gene WDR45 .......................................................... 36 II.1.2.4. The brain-specific Wdr45 knockout mouse model ......................................................................... 36 II.1.2.5. WDR45 and its function in autophagy ............................................................................................ 38 II.2. RESULTS ........................................................................................................................... 41 II.2.1. Clinical presentation in human BPAN patients ................................................................... 41 II.2.2. Generation of a Wdr45 knockout mouse via TALENs ........................................................ 43 II.2.3. Systemic Wdr45 KO is viable in mice .................................................................................... 45 II.2.4. Analysis of preliminary Wdr45 KO mice (F2) shows neurobehavioral deficits ................ 47 II.2.5. Screen of the disease progression Wdr45 cohort (F3) .......................................................... 50 II.2.5.1. Neurologic deterioration in Wdr45 KO mice .................................................................................. 50 II.2.5.2. Pathologic brain abnormalities in Wdr45 KO mice ....................................................................... 54 II.2.6. Secondary screen of aged Wdr45 KO GMC cohort (F4) ..................................................... 58 II.3. DISCUSSION ..................................................................................................................... 59 II.3.1. Of mice and men: the Wdr45 KO mouse as a model for BPAN ......................................... 59 II.3.2. The BPAN mouse model helps investigate disorders of autophagy ................................... 62 II.3.3. From the BPAN mouse model to therapeutic strategies ..................................................... 65 III. THERAPEUTIC STRATEGY FOR GLUTARIC ACIDURIA TYPE 1 .......... 67 III.1. INTRODUCTION .......................................................................................................... 67 III.1.1. The lysine degradation pathway ............................................................................................ 67 III.1.2. Glutaric aciduria type 1 - GCDH .......................................................................................... 69 III.1.3. 2-aminoadipic 2-oxoadipic aciduria – DHTKD1 ................................................................. 71 III.1.4. Glutaric aciduria type 3 – C7ORF10 .................................................................................... 72 III.1.5. DHTKD1 inhibition as a therapy for glutaric aciduria type 1 ........................................... 72 III.2. RESULTS ........................................................................................................................ 73 III.2.1. Generation of a Dhtkd1 KO mouse via TALENs ................................................................. 73 III.2.2. Clinical and biochemical characterization of the Dhtkd1 KO mouse ................................ 75 III.2.3. Generation of a Gcdh/Dhtkd1-double KO mouse................................................................. 77 III.2.4. Biochemical characterization of the double KO mouse ...................................................... 78 6 TABLE OF CONTENTS III.2.5. High-lysine diet challenges knockout lines ............................................................................79 III.3. DISCUSSION .................................................................................................................. 82 III.3.1. DHTKD1 inhibition is not a promising treatment strategy for GA-I .................................82 III.3.2. Murine double KO experiments question the current theory of lysine degradation ........82 III.3.3. Future investigations of the lysine degradation pathway towards GA-I therapy .............83 IV. CONCLUSION AND OUTLOOK ........................................................................ 85 V. MATERIAL AND METHODS ............................................................................. 88 V.1. Material ............................................................................................................................... 88 V.1.1. Chemicals and reagents ..........................................................................................................88 V.1.2. Enzymes and proteins
Load more

Recommended publications
  • Analysis of Trans Esnps Infers Regulatory Network Architecture
    Analysis of trans eSNPs infers regulatory network architecture Anat Kreimer Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2014 Anat Kreimer All rights reserved ABSTRACT Analysis of trans eSNPs infers regulatory network architecture Anat Kreimer eSNPs are genetic variants associated with transcript expression levels. The characteristics of such variants highlight their importance and present a unique opportunity for studying gene regulation. eSNPs affect most genes and their cell type specificity can shed light on different processes that are activated in each cell. They can identify functional variants by connecting SNPs that are implicated in disease to a molecular mechanism. Examining eSNPs that are associated with distal genes can provide insights regarding the inference of regulatory networks but also presents challenges due to the high statistical burden of multiple testing. Such association studies allow: simultaneous investigation of many gene expression phenotypes without assuming any prior knowledge and identification of unknown regulators of gene expression while uncovering directionality. This thesis will focus on such distal eSNPs to map regulatory interactions between different loci and expose the architecture of the regulatory network defined by such interactions. We develop novel computational approaches and apply them to genetics-genomics data in human. We go beyond pairwise interactions to define network motifs, including regulatory modules and bi-fan structures, showing them to be prevalent in real data and exposing distinct attributes of such arrangements. We project eSNP associations onto a protein-protein interaction network to expose topological properties of eSNPs and their targets and highlight different modes of distal regulation.
    [Show full text]
  • S-Like Movement Disorder
    ARTICLE Received 7 Apr 2014 | Accepted 7 Aug 2014 | Published 15 Sep 2014 DOI: 10.1038/ncomms5930 Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson’s-like movement disorder Wei Lu1,*, Senthilkumar S. Karuppagounder2,3,4,*, Danielle A. Springer5, Michele D. Allen5, Lixin Zheng1, Brittany Chao1, Yan Zhang6, Valina L. Dawson2,3,4,7,8, Ted M. Dawson2,3,4,8,9 & Michael Lenardo1 Mitophagy is a specialized form of autophagy that selectively disposes of dysfunctional mitochondria. Delineating the molecular regulation of mitophagy is of great importance because defects in this process lead to a variety of mitochondrial diseases. Here we report that mice deficient for the mitochondrial protein, phosphoglycerate mutase family member 5 (PGAM5), displayed a Parkinson’s-like movement phenotype. We determined biochemically that PGAM5 is required for the stabilization of the mitophagy-inducing protein PINK1 on damaged mitochondria. Loss of PGAM5 disables PINK1-mediated mitophagy in vitro and leads to dopaminergic neurodegeneration and mild dopamine loss in vivo. Our data indicate that PGAM5 is a regulator of mitophagy essential for mitochondrial turnover and serves a cytoprotective function in dopaminergic neurons in vivo. Moreover, PGAM5 may provide a molecular link to study mitochondrial homeostasis and the pathogenesis of a movement disorder similar to Parkinson’s disease. 1 Molecular Development of the Immune System Section, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. 2 Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA. 3 Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
    [Show full text]
  • Clinical Report of a Neonate Carrying a Large Deletion in the 10P15.3P13
    Shao et al. Mol Cytogenet (2021) 14:29 https://doi.org/10.1186/s13039-021-00546-1 CASE REPORT Open Access Clinical report of a neonate carrying a large deletion in the 10p15.3p13 region and review of the literature Qiao‑Yan Shao, Pei‑Lin Wu, Bi‑Yun Lin, Sen‑Jing Chen, Jian Liu and Su‑Qing Chen* Abstract Background: Terminal deletion of chromosome 10p is a rare chromosomal abnormality. We report a neonatal case with a large deletion of 10p15.3p13 diagnosed early because of severe clinical manifestations. Case presentation: Our patient presented with specifc facial features, hypoparathyroidism, sen sorineural deafness, renal abnormalities, and developmental retardation, and carried a 12.6 Mb deletion in the 10p15.3 p13 region. The terminal 10p deletion involved in our patient is the second largest reported terminal deletion reported to date, and includes the ZMYND11 and GATA3 genes and a partial critical region of the DiGeorge syndrome 2 gene (DGS2). Conclusion: On the basis of a literature review, this terminal 10p deletion in the present case is responsible for a spe‑ cifc contiguous gene syndrome. This rare case may help the understanding of the genotype–phenotype spectrum of terminal deletion of chromosome 10p. Keywords: 10p15.3 microdeletion syndrome, HDR syndrome, DiGeorge critical region 2, ZMYND11, GATA3 Background Here, we report a Chinese infant showing specifc Terminal deletion of chromosome 10p is a rare chromo- facial features, congenital hypoparathyroidism, sen- somal disorder. Te haploinsufciency in the distal region sorineural hearing loss, absence of the right kidney, a of 10p15.3 is responsible for 10p15.3 microdeletion syn- sacrococcygeal mass, a right frontal cyst, and psycho- drome (OMIM 608,668), characterized by specifc facial motor retardation.
    [Show full text]
  • UNIVERSITY of CALIFORNIA, SAN DIEGO Functional Analysis of Sall4
    UNIVERSITY OF CALIFORNIA, SAN DIEGO Functional analysis of Sall4 in modulating embryonic stem cell fate A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Molecular Pathology by Pei Jen A. Lee Committee in charge: Professor Steven Briggs, Chair Professor Geoff Rosenfeld, Co-Chair Professor Alexander Hoffmann Professor Randall Johnson Professor Mark Mercola 2009 Copyright Pei Jen A. Lee, 2009 All rights reserved. The dissertation of Pei Jen A. Lee is approved, and it is acceptable in quality and form for publication on microfilm and electronically: ______________________________________________________________ ______________________________________________________________ ______________________________________________________________ ______________________________________________________________ Co-Chair ______________________________________________________________ Chair University of California, San Diego 2009 iii Dedicated to my parents, my brother ,and my husband for their love and support iv Table of Contents Signature Page……………………………………………………………………….…iii Dedication…...…………………………………………………………………………..iv Table of Contents……………………………………………………………………….v List of Figures…………………………………………………………………………...vi List of Tables………………………………………………….………………………...ix Curriculum vitae…………………………………………………………………………x Acknowledgement………………………………………………….……….……..…...xi Abstract………………………………………………………………..…………….....xiii Chapter 1 Introduction ..…………………………………………………………………………….1 Chapter 2 Materials and Methods……………………………………………………………..…12
    [Show full text]
  • The Study of Two Transmembrane Autophagy Proteins and the Autophagy Receptor, P62
    The study of two transmembrane autophagy proteins and the autophagy receptor, p62 Gautam M. Runwal St. John’s College, Cambridge September 2018 This dissertation is submitted for the degree of Doctor of Philosophy Title: The study of two transmembrane autophagy proteins and the autophagy receptor, p62 Submitted by : Gautam M Runwal Abstract Autophagy is an evolutionarily conserved process across eukaryotes that is responsible for degradation of cargo such as aggregate-prone proteins, pathogens, damaged organelles, macromolecules etc. via its delivery to lysosomes. The process is known to involve the formation of a double-membraned structure, called autophagosome, that engulfs the cargo destined for degradation and delivers its contents by fusing with lysosomes. This process involves several proteins at its core which include two transmembrane proteins, ATG9 and VMP1. While ATG9 and VMP1 has been discovered for about a decade and half, the trafficking and function of these proteins remain relatively unclear. My work in this thesis identifies and characterises a novel trafficking route for ATG9 and VMP1 and shows that both these proteins traffic via the dynamin-independent ARF6-associated pathway. Moreover, I also show that these proteins physically interact with each other. In addition, the tools developed during these studies helped me identify a new role for the most common autophagy receptor protein, p62. I show that p62 can specifically associate with and sequester LC3-I in autophagy- impaired cells (ATG9 and ATG16 null cells) leading to formation of LC3-positive structures that can be misinterpreted as mature autophagosomes. Perturbations in the levels of p62 were seen to affect the formation of these LC3-positive structures in cells.
    [Show full text]
  • Inherited Neuropathies
    407 Inherited Neuropathies Vera Fridman, MD1 M. M. Reilly, MD, FRCP, FRCPI2 1 Department of Neurology, Neuromuscular Diagnostic Center, Address for correspondence Vera Fridman, MD, Neuromuscular Massachusetts General Hospital, Boston, Massachusetts Diagnostic Center, Massachusetts General Hospital, Boston, 2 MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology Massachusetts, 165 Cambridge St. Boston, MA 02114 and The National Hospital for Neurology and Neurosurgery, Queen (e-mail: [email protected]). Square, London, United Kingdom Semin Neurol 2015;35:407–423. Abstract Hereditary neuropathies (HNs) are among the most common inherited neurologic Keywords disorders and are diverse both clinically and genetically. Recent genetic advances have ► hereditary contributed to a rapid expansion of identifiable causes of HN and have broadened the neuropathy phenotypic spectrum associated with many of the causative mutations. The underlying ► Charcot-Marie-Tooth molecular pathways of disease have also been better delineated, leading to the promise disease for potential treatments. This chapter reviews the clinical and biological aspects of the ► hereditary sensory common causes of HN and addresses the challenges of approaching the diagnostic and motor workup of these conditions in a rapidly evolving genetic landscape. neuropathy ► hereditary sensory and autonomic neuropathy Hereditary neuropathies (HN) are among the most common Select forms of HN also involve cranial nerves and respiratory inherited neurologic diseases, with a prevalence of 1 in 2,500 function. Nevertheless, in the majority of patients with HN individuals.1,2 They encompass a clinically heterogeneous set there is no shortening of life expectancy. of disorders and vary greatly in severity, spanning a spectrum Historically, hereditary neuropathies have been classified from mildly symptomatic forms to those resulting in severe based on the primary site of nerve pathology (myelin vs.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Identification of FBXL4 As a Metastasis Associated Gene in Prostate Cancer
    Identification of FBXL4 as a Metastasis Associated Gene in Prostate Cancer Elzbieta Stankiewicz1 , Xueying Mao1, D Chas Mangham2 , Lei Xu1, Marc Yeste- Velasco1, Gabrielle Fisher3, Bernard North3, Tracy Chaplin1, Bryan Young4, Yuqin Wang1, Jasmin Kaur Bansal1, Sakunthala Kudahetti1, Lucy Spencer1, Christopher S Foster5, Henrik Moller6, Peter Scardino7, R Tim Oliver1, Jonathan Shamash1, Jack Cuzick3, Colin S Cooper8, Daniel M Berney1,+, Yong-Jie Lu1,+,* 1 Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK 2 The Robert Jones and Agnes Hunt Orthopaedic Hospital, Department of Pathology, Oswestry, Shropshire SY10 7AG, UK 3 Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London EC1 6BQ, UK 4 Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK 5 Division of Cellular and Molecular Pathology, University of Liverpool, Liverpool L69 3BX, UK 6 King's College London, Cancer Epidemiology and Population Health, London SE1 9RT, UK 7 Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA 1 8 School of Medicine, University of East Anglia, Norwich, NR4 7TJ, UK +These authors contributed equally as senior role *Corresponding author: Yong-Jie Lu, Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, Telephone number: 442078823563, Fax: 442078823884, e-mail address: [email protected] 2 Abstract Prostate cancer is the most common cancer among western men, with a significant mortality and morbidity reported for advanced metastatic disease. Current understanding of metastatic disease is limited due to difficulty of sampling as prostate cancer mainly metastasizes to bone.
    [Show full text]
  • Genetic and Genomic Analysis of Hyperlipidemia, Obesity and Diabetes Using (C57BL/6J × TALLYHO/Jngj) F2 Mice
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Nutrition Publications and Other Works Nutrition 12-19-2010 Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P. Stewart Marshall University Hyoung Y. Kim University of Tennessee - Knoxville, [email protected] Arnold M. Saxton University of Tennessee - Knoxville, [email protected] Jung H. Kim Marshall University Follow this and additional works at: https://trace.tennessee.edu/utk_nutrpubs Part of the Animal Sciences Commons, and the Nutrition Commons Recommended Citation BMC Genomics 2010, 11:713 doi:10.1186/1471-2164-11-713 This Article is brought to you for free and open access by the Nutrition at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Nutrition Publications and Other Works by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. Stewart et al. BMC Genomics 2010, 11:713 http://www.biomedcentral.com/1471-2164/11/713 RESEARCH ARTICLE Open Access Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P Stewart1, Hyoung Yon Kim2, Arnold M Saxton3, Jung Han Kim1* Abstract Background: Type 2 diabetes (T2D) is the most common form of diabetes in humans and is closely associated with dyslipidemia and obesity that magnifies the mortality and morbidity related to T2D. The genetic contribution to human T2D and related metabolic disorders is evident, and mostly follows polygenic inheritance. The TALLYHO/ JngJ (TH) mice are a polygenic model for T2D characterized by obesity, hyperinsulinemia, impaired glucose uptake and tolerance, hyperlipidemia, and hyperglycemia.
    [Show full text]
  • Alzheimer Disease
    ManuscriptPreprints (www.preprints.org) - with full author details | NOT PEER-REVIEWED | Posted: 4 June 2020 AN ATLAS OF THE GENETIC VARIATIONS LINKING DYSREGULATION OF AUTOPHAGY TO HUMAN DISEASES: THE MISSING ENVIRONMENTAL LINK Iris Grosjean 1*, Barnabé Roméo 1*, Marie-Angela Domdom 1, Nathalie Yazbeck 1, Grégoire D’Andréa 1,2, Amine Belaid 3, Olivier Camuzard4, Olivia Vidal 1, Guillemette Crépeaux 5,6, Romain K Gherardi 6, François Jerome Authier 6, Jean Daniel Masson 6, Eric Gilson 1,7, Charles Hugo Marquette1,8, Sylvie Leroy 8, Jérémie Roux 1, Patrick Brest 1, Martin Von Bergen 9, Gérard Milano 10, Daniel J. Klionsky 11, Paul Hofman 1,12, Baharia Mograbi 1# 1. University Côte d'Azur, CNRS, INSERM, IRCAN, FHU-OncoAge, Centre Antoine Lacassagne, Nice, France. 2. University Côte d'Azur, Institut Universitaire de la Face et du Cou, ENT and Cervico-Facial Surgery department, CHU de Nice, Nice, France. 3. Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA 4. University Côte d'Azur, UMR E-4320 TIRO-MATOs CEA/DRF/BIAM, Faculté de Médecine, Service de Chirurgie Réparatrice et de la Main, CHU de Nice, Nice, France. 5. Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France. 6. INSERM U955 Team Relais, Faculty of Health, Paris Est University, Créteil, France. 7. Department of Medical Genetics, Archet 2 Hospital, CHU of Nice, Nice, France. 8. University Côte d'Azur, FHU-OncoAge, Department of Pulmonary Medicine and Oncology, CHU de Nice, Nice, France. 9. Helmholtz Centre for Environmental Research GmbH - UFZ, Dep.
    [Show full text]
  • PANK2 Gene Pantothenate Kinase 2
    PANK2 gene pantothenate kinase 2 Normal Function The PANK2 gene provides instructions for making an enzyme called pantothenate kinase 2. This enzyme is active in specialized cellular structures called mitochondria, which are the cell's energy-producing centers. Within mitochondria, pantothenate kinase 2 regulates the formation of a molecule called coenzyme A. Coenzyme A is found in all living cells, where it is essential for the body's production of energy from carbohydrates, fats, and some protein building blocks (amino acids). PANK2 is one of four human genes that provide instructions for making versions of pantothenate kinase. The functions of these different versions probably vary among tissue types and parts of the cell. The version produced by the PANK2 gene is active in cells throughout the body, including nerve cells in the brain. Health Conditions Related to Genetic Changes Pantothenate kinase-associated neurodegeneration About 100 mutations in the PANK2 gene have been identified in people with pantothenate kinase-associated neurodegeneration. Typically, people with the more severe, early-onset form of the disorder have PANK2 mutations that prevent cells from producing any functional pantothenate kinase 2. People affected by the atypical, later- onset form usually have mutations that change single amino acids in the enzyme, which makes the enzyme unstable or disrupts its activity. In some cases, single amino acid changes allow the enzyme to retain some function. The most common PANK2 mutation replaces the amino acid glycine with the amino acid arginine at position 411 of the enzyme (written as Gly411Arg or G411R). When pantothenate kinase 2 is altered or missing, the normal production of coenzyme A is disrupted and potentially harmful compounds can build up in the brain.
    [Show full text]
  • Análise Integrativa De Perfis Transcricionais De Pacientes Com
    UNIVERSIDADE DE SÃO PAULO FACULDADE DE MEDICINA DE RIBEIRÃO PRETO PROGRAMA DE PÓS-GRADUAÇÃO EM GENÉTICA ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Ribeirão Preto – 2012 ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Tese apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo para obtenção do título de Doutor em Ciências. Área de Concentração: Genética Orientador: Prof. Dr. Eduardo Antonio Donadi Co-orientador: Prof. Dr. Geraldo A. S. Passos Ribeirão Preto – 2012 AUTORIZO A REPRODUÇÃO E DIVULGAÇÃO TOTAL OU PARCIAL DESTE TRABALHO, POR QUALQUER MEIO CONVENCIONAL OU ELETRÔNICO, PARA FINS DE ESTUDO E PESQUISA, DESDE QUE CITADA A FONTE. FICHA CATALOGRÁFICA Evangelista, Adriane Feijó Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas. Ribeirão Preto, 2012 192p. Tese de Doutorado apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. Área de Concentração: Genética. Orientador: Donadi, Eduardo Antonio Co-orientador: Passos, Geraldo A. 1. Expressão gênica – microarrays 2. Análise bioinformática por module maps 3. Diabetes mellitus tipo 1 4. Diabetes mellitus tipo 2 5. Diabetes mellitus gestacional FOLHA DE APROVAÇÃO ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas.
    [Show full text]